2 news items
Generics Player Teva Pharmaceutical Aces Late-Stage Schizophrenia Drug Study, Stock Shoots Higher
TEVA
8 May 24
, partially offset by lower revenues from Copaxone.
Generic products revenues were $808 million, up 8%, mainly due
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
TEVA
8 May 24
revenues from generic products in all our segments, from AUSTEDO, as well as from AJOVY in our Europe and International Markets segments, partially offset
- Prev
- 1
- Next